<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="brief-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Brain</journal-id>
<journal-id journal-id-type="iso-abbrev">Brain</journal-id>
<journal-id journal-id-type="publisher-id">brainj</journal-id>
<journal-title-group>
<journal-title>Brain</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-8950</issn>
<issn pub-type="epub">1460-2156</issn>
<publisher>
<publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31504246</article-id>
<article-id pub-id-type="pmc">6821231</article-id>
<article-id pub-id-type="doi">10.1093/brain/awz264</article-id>
<article-id pub-id-type="publisher-id">awz264</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reports</subject>
</subj-group>
<subj-group subj-group-type="category-oup-series">
<subject>Editor's Choice</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>
<italic>De novo</italic> variants in <italic>PAK1</italic> lead to intellectual disability with macrocephaly and seizures</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-2902-0377</contrib-id>
<name>
<surname>Horn</surname>
<given-names>Susanne</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff1">1</xref>
<xref ref-type="corresp" rid="awz264-cor1"></xref>
<!--<email>Susanne.Horn@medizin.uni-leipzig.de</email>-->
</contrib>
<contrib contrib-type="author">
<name>
<surname>Au</surname>
<given-names>Margaret</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Basel-Salmon</surname>
<given-names>Lina</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff3">3</xref>
<xref ref-type="aff" rid="awz264-aff4">4</xref>
<xref ref-type="aff" rid="awz264-aff5">5</xref>
<xref ref-type="aff" rid="awz264-aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bayrak-Toydemir</surname>
<given-names>Pinar</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chapin</surname>
<given-names>Alexander</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cohen</surname>
<given-names>Lior</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff3">3</xref>
<xref ref-type="aff" rid="awz264-aff4">4</xref>
<xref ref-type="aff" rid="awz264-aff5">5</xref>
<xref ref-type="aff" rid="awz264-aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Elting</surname>
<given-names>Mariet W</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Graham</surname>
<given-names>John M</given-names>
<suffix>Jr</suffix>
</name>
<xref ref-type="aff" rid="awz264-aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gonzaga-Jauregui</surname>
<given-names>Claudia</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Konen</surname>
<given-names>Osnat</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff5">5</xref>
<xref ref-type="aff" rid="awz264-aff11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Holzer</surname>
<given-names>Max</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff12">12</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-4435-6610</contrib-id>
<name>
<surname>Lemke</surname>
<given-names>Johannes</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Miller</surname>
<given-names>Christine E</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rey</surname>
<given-names>Linda K</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff13">13</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-1721-0728</contrib-id>
<name>
<surname>Wolf</surname>
<given-names>Nicole I</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff14">14</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Weiss</surname>
<given-names>Marjan M</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Waisfisz</surname>
<given-names>Quinten</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mirzaa</surname>
<given-names>Ghayda M</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff15">15</xref>
<xref ref-type="aff" rid="awz264-aff16">16</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wieczorek</surname>
<given-names>Dagmar</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff13">13</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sticht</surname>
<given-names>Heinrich</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff17">17</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Abou Jamra</surname>
<given-names>Rami</given-names>
</name>
<xref ref-type="aff" rid="awz264-aff1">1</xref>
<xref ref-type="corresp" rid="awz264-cor2"></xref>
<!--<email>rami.aboujamra@medizin.uni-leipzig.de</email>-->
</contrib>
</contrib-group>
<aff id="awz264-aff1"><label>1</label>
<institution>Institute of Human Genetics, University Medical Center Leipzig</institution>, Leipzig, Germany</aff>
<aff id="awz264-aff2"><label>2</label>
<institution>Department of Pediatrics, Cedars Sinai Medical Center</institution>, David Geffen School of Medicine at UCLA, Los Angeles, California, USA</aff>
<aff id="awz264-aff3"><label>3</label>
<institution>Raphael Recanati Genetic Institute, Rabin Medical Center-Beilinson Hospital</institution>, Petach Tikva, Israel</aff>
<aff id="awz264-aff4"><label>4</label>
<institution>Pediatric Genetics Clinic, Schneider Children’s Medical Center of Israel</institution>, Petach Tikva, Israel</aff>
<aff id="awz264-aff5"><label>5</label>
<institution>Sackler Faculty of Medicine, Tel Aviv University</institution>, Tel Aviv, Israel</aff>
<aff id="awz264-aff6"><label>6</label>
<institution>Felsenstein Medical Research Center, Rabin Medical Center</institution>, Petach Tikva, Israel</aff>
<aff id="awz264-aff7"><label>7</label>
<institution>Department of Pathology, University of Utah School of Medicine</institution>, Salt Lake City, UT, USA; ARUP Laboratories, Salt Lake City, UT, USA</aff>
<aff id="awz264-aff8"><label>8</label>
<institution>ARUP Laboratories</institution>, Salt Lake City, UT, USA</aff>
<aff id="awz264-aff9"><label>9</label>
<institution>Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Clinical Genetics</institution>, De Boelelaan 1117, Amsterdam, The Netherlands</aff>
<aff id="awz264-aff10"><label>10</label>
<institution>Regeneron Genetics Center, Regeneron Pharmaceuticals Inc.</institution>, Tarrytown, NY, USA</aff>
<aff id="awz264-aff11"><label>11</label>
<institution>Department of Pediatric Radiology, Schneider Children’s Medical Center of Israel, Petach Tikva</institution>, Israel</aff>
<aff id="awz264-aff12"><label>12</label>
<institution>Department for Molecular and Cellular Mechanisms of Neurodegeneration</institution>, Paul Flechsig Institute for Brain Research, University of Leipzig, Leipzig, Germany</aff>
<aff id="awz264-aff13"><label>13</label>
<institution>Institute of Human Genetics, University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf</institution>, Duesseldorf, Germany</aff>
<aff id="awz264-aff14"><label>14</label>
<institution>Department of Child Neurology, Emma Children’s Hospital</institution>, Amsterdam UMC, Vrije Universiteit Amsterdam, and Amsterdam Neuroscience, Amsterdam, The Netherlands</aff>
<aff id="awz264-aff15"><label>15</label>
<institution>Center for Integrative Brain Research, Seattle Children’s Research Institute</institution>, Seattle, Washington, USA</aff>
<aff id="awz264-aff16"><label>16</label>
<institution>Department of Pediatrics, University of Washington</institution>, Seattle, Washington, USA</aff>
<aff id="awz264-aff17"><label>17</label>
<institution>Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg</institution>, Erlangen, Germany</aff>
<author-notes>
<corresp id="awz264-cor1">Correspondence to: Dr Susanne Horn Institute of Human Genetics, University Medical Center Leipzig, 04103 Leipzig, Germany E-mail: <email>Susanne.Horn@medizin.uni-leipzig.de</email></corresp>
<corresp id="awz264-cor2">Correspondence may also be addressed to: Dr Rami Abou Jamra E-mail: <email>rami.aboujamra@medizin.uni-leipzig.de</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date iso-8601-date="2019-08-29" pub-type="epub">
<day>29</day>
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>29</day>
<month>8</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>142</volume>
<issue>11</issue>
<fpage>3351</fpage>
<lpage>3359</lpage>
<history>
<date date-type="received">
<day>2</day>
<month>10</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>7</day>
<month>6</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>4</day>
<month>7</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. </copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
</license>
</permissions>
<self-uri xlink:href="awz264.pdf"></self-uri>
<abstract abstract-type="teaser">
<p>Using trio exome sequencing, Horn <italic>et al.</italic> identify <italic>de novo</italic> gain-of-function mutations in <italic>PAK1</italic> in four unrelated individuals with intellectual disability, macrocephaly and seizures. <italic>PAK1</italic> encodes a p21-activated kinase, which has been implicated in brain development and control of brain size.</p>
</abstract>
<abstract>
<title>Abstract</title>
<p>Using trio exome sequencing, we identified <italic>de novo</italic> heterozygous missense variants in <italic>PAK1</italic> in four unrelated individuals with intellectual disability, macrocephaly and seizures. <italic>PAK1</italic> encodes the p21-activated kinase, a major driver of neuronal development in humans and other organisms. In normal neurons, PAK1 dimers reside in a trans-inhibited conformation, where each autoinhibitory domain covers the kinase domain of the other monomer. Upon GTPase binding via CDC42 or RAC1, the PAK1 dimers dissociate and become activated. All identified variants are located within or close to the autoinhibitory switch domain that is necessary for trans-inhibition of resting PAK1 dimers. Protein modelling supports a model of reduced ability of regular autoinhibition, suggesting a gain of function mechanism for the identified missense variants. Alleviated dissociation into monomers, autophosphorylation and activation of PAK1 influences the actin dynamics of neurite outgrowth. Based on our clinical and genetic data, as well as the role of <italic>PAK1</italic> in brain development, we suggest that gain of function pathogenic <italic>de novo</italic> missense variants in <italic>PAK1</italic> lead to moderate-to-severe intellectual disability, macrocephaly caused by the presence of megalencephaly and ventriculomegaly, (febrile) seizures and autism-like behaviour.</p>
</abstract>
<kwd-group>
<kwd>
<italic>de novo</italic>
</kwd>
<kwd>exome sequencing</kwd>
<kwd>intellectual disability</kwd>
<kwd>macrocephaly</kwd>
<kwd>seizures</kwd>
</kwd-group>
<funding-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">National Institute of Neurological Disorders and Stroke (NINDS)</named-content>
</funding-source>
<award-id>K08NS092898</award-id>
</award-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">Jordan’s Guardian Angels</named-content>
</funding-source>
</award-group>
<award-group award-type="grant">
<funding-source>
<named-content content-type="funder-name">National Institutes of Health</named-content>
<named-content content-type="funder-identifier">10.13039/100000002</named-content>
</funding-source>
</award-group>
</funding-group>
<counts>
<page-count count="9"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>With a prevalence of about 1–3%, intellectual disability is a major health and socioeconomic issue (<xref ref-type="bibr" rid="awz264-B19">Maulik <italic>et al.</italic>, 2011</xref>). Intellectual disability is genetically highly heterogeneous, with each recognized cause affecting only a small fraction of all patients (<xref ref-type="bibr" rid="awz264-B30">Vissers <italic>et al.</italic>, 2016</xref>). Services for people with intellectual disability increasingly focus on innovative and personalized therapies. Major research efforts have used efficient molecular diagnostic tools for rare diseases, especially exome sequencing given its high diagnostic yield (<xref ref-type="bibr" rid="awz264-B5">Ligt <italic>et al.</italic>, 2012</xref>; <xref ref-type="bibr" rid="awz264-B2">Boycott <italic>et al.</italic>, 2017</xref>; <xref ref-type="bibr" rid="awz264-B28">Trujillano <italic>et al.</italic>, 2017</xref>), thus providing knowledge of specific genetic variants as a prerequisite for personalized therapy in cases where mechanistic insights on the affected genes and proteins exist.</p>
<p>At four centres in Germany, the Netherlands, the USA and Israel, we ascertained four unrelated individuals with a neurodevelopmental disorder, including intellectual disability, seizures and macrocephaly. We performed exome sequencing to identify the underlying genetic cause of the disease. Here we present data that indicate a pathogenic mechanism of <italic>PAK1</italic> mutations by a dominant gain-of-function effect. <italic>De novo PAK1</italic> missense pathogenic variants have also recently been described in two cases with intellectual disability, macrocephaly, seizures and speech delay (MIM: 618158) (<xref ref-type="bibr" rid="awz264-B8">Harms <italic>et al.</italic>, 2018</xref>). Human PAK1 is a 545-amino acid (aa) protein with two major domains, an autoregulatory domain and a protein kinase domain (<xref ref-type="fig" rid="awz264-F1">Fig. 1</xref>). In its inactive form, it homodimerizes by interacting and binding at a region within the autoregulatory domain (74–132 aa) masking the active site of the kinase. Therefore the autoregulatory domain is important for the autoinhibition of this kinase, and this mechanism has been well described for PAK1 (<xref ref-type="bibr" rid="awz264-B15">Lei <italic>et al.</italic>, 2000</xref>; <xref ref-type="bibr" rid="awz264-B21">Parrini <italic>et al.</italic>, 2002</xref>; <xref ref-type="bibr" rid="awz264-B23">Pirruccello <italic>et al.</italic>, 2006</xref>). In the inhibited state, the inhibitory-switch domain of one homodimer overlaps the GTPase binding region (75–105 aa) of the other homodimer and a polypeptide segment covers the kinase cleft (<xref ref-type="bibr" rid="awz264-B21">Parrini <italic>et al.</italic>, 2002</xref>). During activation, GTPase binding triggers refolding of the inhibitory-switch domain, disrupting the PAK1 dimer and leading to rearrangement of the kinase active site into a catalytically competent state.
</p>
<fig id="awz264-F1" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>
<bold>Structural effects of the PAK1 variants.</bold> (<bold>A</bold>) Protein structure of PAK1 with the catalytic domain (270–521 aa, blue) and the autoinhibitory domain (70–140 aa), comprising the Cdc42 Rac Interactive Binding (CRIB) domain (75–86 aa, green) and the inhibitory switch domain (87–136 aa, red, <ext-link ext-link-type="uri" xlink:href="https://www.uniprot.org">https://www.uniprot.org</ext-link>). Variants Leu470Arg, Ser133Pro and Ser110Thr affect the contact zone of the catalytic and inhibitory switch domains. Pro121Ser is located in the interface between both PAK1 monomers (see also <xref ref-type="supplementary-material" rid="sup1">Supplementary Fig. 1</xref>). The CRIB domain (green) mediates activation of PAK1 by binding of RAC1 and CDC42. (<bold>B</bold>) Autoinhibiton of PAK1. Autoinhibitory domains (light red) of inactive dimers cover the active site <italic>in-trans.</italic> After CDC42 or RAC1 binding, monomers dissociate, PAK1 autophosphorylation creates the active form of the protein. (<bold>C</bold>) Distribution of PAK1 variants across the coding region. (<bold>D</bold> and <bold>E</bold>) Leu470 forms tight hydrophobic interactions with Leu106, whereas the longer and charged Arg470 sidechain results in clashes with Leu106. In all panels the site of mutation is shown in space-filled presentation and coloured according to the atom types. Key interacting residues are shown in space-fill and are coloured orange or cyan. The two subunits of PAK1 are shown as red and blue ribbon, respectively. Sites of unfavourable interactions in the variants are highlighted by dashed circles. (<bold>F</bold> and <bold>G</bold>) Ser110 interacts with Leu106, whereas the additional methyl group present in the Thr110 sidechain forms clashes with Leu106. (<bold>H</bold> and <bold>I</bold>) Ser133 forms a backbone hydrogen bond with Glu129 within an α-helix. The presence of a cyclic sidechain in Pro133 results in a loss of this hydrogen bond and additionally causes steric clashes with Glu129. (<bold>J</bold> and <bold>K</bold>) Pro121 is located at a kink between two α-helices and near Phe81 of the second subunit. Replacement by a more flexible serine is expected to destabilize the kink and additionally creates an unfavourable interaction by placing the polar sidechain hydroxyl group in close proximity to the hydrophobic Phe81 sidechain.</p>
</caption>
<graphic xlink:href="awz264f1"></graphic>
</fig>
<p>We propose that PAK1 disease-causing variants result in activation of the PAK1-LIMK1 pathway, a mechanism that is discussed in fragile X syndrome (FXS) (<xref ref-type="bibr" rid="awz264-B9">Hayashi <italic>et al.</italic>, 2007</xref>; <xref ref-type="bibr" rid="awz264-B24">Pyronneau <italic>et al.</italic>, 2017</xref>).</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec sec-type="subjects">
<title>Subjects</title>
<p>Informed consent of all examined individuals and/or their guardians was obtained according to Institutional Review Board approved research protocols, including consent for publishing of the clinical as well as the genetic and genomic results. In Proband 4, genetic testing was carried out as part of routine clinical care and therefore institutional ethics approval was not required. Informed consent has been obtained for the published photo.</p>
</sec>
<sec>
<title>Exome sequencing</title>
<p>The study design comprised whole exome-sequencing (WES), genotype calling and the comparison of parent-offspring trios for the identification of rare variants in coding sequence associated with the observed human phenotype. We performed trio or family exome sequencing for all four probands and their biological parents according to standard methods (<xref ref-type="supplementary-material" rid="sup1">Supplementary material</xref>). Reported variants for all individuals were confirmed with Sanger dideoxynucleotide sequencing.</p>
</sec>
<sec>
<title>Protein modelling and analysis of gene expression</title>
<p>Energetic calculations of the observed protein changes were carried out using BindProfX (<xref ref-type="bibr" rid="awz264-B31">Xiong <italic>et al.</italic>, 2017</xref>) and visualized using UCSC Chimera v.1.12 (<xref ref-type="bibr" rid="awz264-B22">Pettersen <italic>et al.</italic>, 2004</xref>). To determine an unbiased set of relevant PAK1 interacting genes for comparisons, we analysed gene expression in normal brain development using the R2 Genomics analysis and visualization platform (dataset brspv10rs). Interacting genes were predicted by using GENEMANIA (<ext-link ext-link-type="uri" xlink:href="https://genemania.org">https://genemania.org</ext-link>).</p>
</sec>
<sec>
<title>Limitations of the study</title>
<p>Limitations of the retrospective case series are to be noted as there is limited information on the seizure types of the patients, with respect to detailed descriptions of seizures and post-ictal symptoms to classify them in more detail.</p>
</sec>
<sec sec-type="data-availability">
<title>Data availability</title>
<p>The authors confirm that the data supporting the findings of this study are available within the article and/or its <xref ref-type="supplementary-material" rid="sup1">Supplementary material</xref>.</p>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<p>The probands presented with moderate to profound intellectual disability, seizures, macrocephaly, ventriculomegaly and other abnormalities in brain MRI, muscular hypotonia, and abnormal gait (<xref ref-type="table" rid="awz264-T1">Table 1</xref>, see detailed clinical descriptions in the <xref ref-type="supplementary-material" rid="sup1">Supplementary material</xref>). The analyses revealed <italic>de novo</italic> missense variants in <italic>PAK1</italic> in the four probands, c.1409T&gt;G in exon 13 of 16 leading to p.(Leu470Arg) in Proband 1, and three changes in exon 4: c.397T&gt;C; p.(Ser133Pro) in Proband 2, c.361C&gt;T; p.(Pro121Ser) in Proband 3, and c.328T&gt;A; p.(Ser110Thr) in Proband 4 (<xref ref-type="table" rid="awz264-T1">Table 1</xref> and <xref ref-type="supplementary-material" rid="sup1">Supplementary Table 1</xref>). None of the variants in <italic>PAK1</italic> have been observed in the gnomAD database (accessed in September 2018) or in internal databases. All of the variants are predicted to be pathogenic by <italic>in silico</italic> bioinformatics prediction algorithms and reaching between the top 1% and 0.1% CADD scores (<xref ref-type="bibr" rid="awz264-B14">Kircher <italic>et al.</italic>, 2014</xref>). In addition, all variants affect highly conserved amino acid residues and nucleotides, except for a moderately conserved nucleotide in Proband 4. <italic>PAK1</italic> shows fewer missense variants than expected by chance with a z-score of 4.16 (<xref ref-type="bibr" rid="awz264-B16">Lek <italic>et al.</italic>, 2016</xref>), suggesting that heterozygous missense variants are less tolerated. In addition, <italic>in silico</italic> modelling of protein structures of wild-type and altered PAK1 revealed that all four identified variants similarly lead to a disturbance of the autoinhibition mechanism (<xref ref-type="fig" rid="awz264-F1">Fig. 1</xref>).
</p>
<table-wrap id="awz264-T1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<p>Clinical features of individuals with predicted missense variants in <italic>PAK1</italic></p>
</caption>
<table frame="hsides" rules="groups">
<thead align="left">
<tr>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1">Proband 1</th>
<th colspan="1" rowspan="1">Proband 2</th>
<th colspan="1" rowspan="1">Proband 3</th>
<th colspan="1" rowspan="1">Proband 4</th>
</tr>
</thead>
<tbody align="left">
<tr>
<td colspan="1" rowspan="1">cDNA change</td>
<td colspan="1" rowspan="1">c.1409T&gt;G</td>
<td colspan="1" rowspan="1">c.397T&gt;C</td>
<td colspan="1" rowspan="1">c.361C&gt;T</td>
<td colspan="1" rowspan="1">c.328T&gt;A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Amino acid change</td>
<td colspan="1" rowspan="1">p.(Leu470Arg)</td>
<td colspan="1" rowspan="1">(p.Ser133Pro)</td>
<td colspan="1" rowspan="1">p.(Pro121Ser)</td>
<td colspan="1" rowspan="1">p.(Ser110Thr)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Ethnicity</td>
<td colspan="1" rowspan="1">Caucasian</td>
<td colspan="1" rowspan="1">Caucasian</td>
<td colspan="1" rowspan="1">Morocco</td>
<td colspan="1" rowspan="1">Sephardi Jew</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Age at last exam/Sex</td>
<td colspan="1" rowspan="1">4 y/Female</td>
<td colspan="1" rowspan="1">17 y/Male</td>
<td colspan="1" rowspan="1">20 y/Male</td>
<td colspan="1" rowspan="1">8 y/Male</td>
</tr>
<tr>
<td colspan="1" rowspan="1">HC last examination</td>
<td colspan="1" rowspan="1">55.5 cm (&gt;P99 +3.80 SD)</td>
<td colspan="1" rowspan="1">59.8 cm (P98 +2.07 SD)</td>
<td colspan="1" rowspan="1">61.5 cm (&gt;P99 +2.95 SD)</td>
<td colspan="1" rowspan="1">59.5 cm (&gt;P99 +4.93 SD)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">BMI</td>
<td colspan="1" rowspan="1">13.9 (P14 −1.09 SD)</td>
<td colspan="1" rowspan="1">Not measured</td>
<td colspan="1" rowspan="1">24.7 (P84 +0.98 SD)</td>
<td colspan="1" rowspan="1">15.3 (P33 −0.45 SD)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Pregnancy</td>
<td colspan="1" rowspan="1">Maternal gestational diabetes, pre-eclampsia</td>
<td colspan="1" rowspan="1">No anomalies</td>
<td colspan="1" rowspan="1">No anomalies</td>
<td colspan="1" rowspan="1">Choroid plexus cyst</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Birth at gestational week</td>
<td colspan="1" rowspan="1">30 weeks</td>
<td colspan="1" rowspan="1">32 weeks</td>
<td colspan="1" rowspan="1">34 weeks</td>
<td colspan="1" rowspan="1">40 weeks</td>
</tr>
<tr>
<td colspan="1" rowspan="4">Birth parameters</td>
<td colspan="1" rowspan="1">Weight 1120 g (P25 −0.69 SD)</td>
<td colspan="1" rowspan="1">Weight 2268 g (P86 +1.07 SD)</td>
<td colspan="1" rowspan="1">Weight 2100 g (P34 −0.4 SD)</td>
<td colspan="1" rowspan="1">Weight 2800 g (P3 −1.87SD)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Length 41 cm (P67 +0.45 SD)</td>
<td colspan="1" rowspan="1">Length NA</td>
<td colspan="1" rowspan="1">Length NA</td>
<td colspan="1" rowspan="1">Length NA</td>
</tr>
<tr>
<td colspan="1" rowspan="1">HC 27.5 cm (P43 −0.18 SD)</td>
<td colspan="1" rowspan="1">HC NA</td>
<td colspan="1" rowspan="1">HC NA</td>
<td colspan="1" rowspan="1">HC 34.5 cm (P20 −0.85 SD)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">APGAR 8/9/10</td>
<td colspan="1" rowspan="1">APGAR NA</td>
<td colspan="1" rowspan="1">APGAR 6/8/9</td>
<td colspan="1" rowspan="1">APGAR NA</td>
</tr>
<tr>
<td colspan="1" rowspan="2">Neonatal period</td>
<td colspan="1" rowspan="1">Primary C-section</td>
<td colspan="1" rowspan="2">Spontaneous uncomplicated premature vaginal delivery NICU 4 weeks</td>
<td colspan="1" rowspan="1">IRDS, 4 days artificial respiration (CPAP and IPPV)</td>
<td colspan="1" rowspan="2">NA</td>
</tr>
<tr>
<td colspan="1" rowspan="1">NICU</td>
<td colspan="1" rowspan="1">Neonatal jaundice (phototherapy for 3 days)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Congenital anomalies</td>
<td colspan="1" rowspan="1">Partial 2–4 toe syndactyly; long fingers</td>
<td colspan="1" rowspan="1">Partial 2–3 toe syndactyly; macrocephaly</td>
<td colspan="1" rowspan="1">No anomalies</td>
<td colspan="1" rowspan="1">No anomalies</td>
</tr>
<tr>
<td colspan="1" rowspan="3">Postnatal growth (Strauss <italic>et al.</italic>, 2018), HC</td>
<td colspan="1" rowspan="1">At 3 months: HC 37 cm (P89 +1.2 SD)</td>
<td colspan="1" rowspan="3">At 13 months: HC 52 cm (&gt;P99 +3.96 SD), length 76 cm (P26 −0.65SD), weight 10.84 kg (P62 +0.31SD)</td>
<td colspan="1" rowspan="3">At 12 y: HC 59 cm (&gt;P99 +3.27 SD), length 140 cm (P7 −1.49 SD)</td>
<td colspan="1" rowspan="3">At 18 months: HC 58 cm (&gt;P99 +7.76 SD)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">At 6 months: HC 43.5 cm (P97 +1.9 SD)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">At 12 months: HC 48.3 cm (&gt;P97 +2.75 SD)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Developmental delay</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Yes</td>
<td colspan="1" rowspan="1">Yes</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Intellectual disability</td>
<td colspan="1" rowspan="1">Moderate to severe</td>
<td colspan="1" rowspan="1">Profound</td>
<td colspan="1" rowspan="1">Moderate to severe</td>
<td colspan="1" rowspan="1">Profound</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Speech and language</td>
<td colspan="1" rowspan="1">Delayed, no active speech</td>
<td colspan="1" rowspan="1">Non-verbal</td>
<td colspan="1" rowspan="1">Delayed, sentences at age of 10 y</td>
<td colspan="1" rowspan="1">Non-verbal</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Mental health disorders</td>
<td colspan="1" rowspan="1">Autistic traits</td>
<td colspan="1" rowspan="1">Autism</td>
<td colspan="1" rowspan="1">ADHD</td>
<td colspan="1" rowspan="1">Autism</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Facial dysmorphism/physical signs</td>
<td colspan="1" rowspan="1">Macrocephaly, frontal bossing, thin upper vermillion, broad nasal bridge, low-set posteriorly rotated ears</td>
<td colspan="1" rowspan="1">Craniofacial disproportion</td>
<td colspan="1" rowspan="1">Macrocephaly</td>
<td colspan="1" rowspan="1">Macrocephaly, strabismus</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Muscular tone</td>
<td colspan="1" rowspan="1">Hypotonia</td>
<td colspan="1" rowspan="1">Initial hypotonia, later spastic quadriplegia</td>
<td colspan="1" rowspan="1">First year hypotonia</td>
<td colspan="1" rowspan="1">Hypotonia</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Walking abilities</td>
<td colspan="1" rowspan="1">Unstable gait</td>
<td colspan="1" rowspan="1">No walking</td>
<td colspan="1" rowspan="1">Walking, mild ataxia</td>
<td colspan="1" rowspan="1">Ataxic, unstable gait</td>
</tr>
<tr>
<td colspan="1" rowspan="2">Brain/MRI</td>
<td colspan="1" rowspan="2">MRI: thin corpus callosum, ventriculomegaly, globular and mildly amorphous hippocampi bilaterally</td>
<td colspan="1" rowspan="2">MRI: thin corpus callosum, cerebellar atrophy with widening of the sulci, megalencephaly, ventriculomegaly, mildly small and amorphous hippocampi bilaterally</td>
<td colspan="1" rowspan="1">MRI: thick corpus callosum, non-specific white matter anomalies of the deep white matter, bilateral and parietal, and of splenium of corpus callosum.</td>
<td colspan="1" rowspan="2">MRI: thick corpus callosum, high bilateral signal intensity in frontal subcortical region</td>
</tr>
<tr>
<td colspan="1" rowspan="1">MRS (spectroscopy): in white matter strongly increased total NAA (not in cortex)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Seizures</td>
<td colspan="1" rowspan="1">At age 19–21 months three febrile seizures, seizures with awareness impairment and myoclonic seizures</td>
<td colspan="1" rowspan="1">Starting age 6 y, atonic, tonic-clonic seizures</td>
<td colspan="1" rowspan="1">One typical febrile seizure (age not known)</td>
<td colspan="1" rowspan="1">Starting age 1.5 y, focal epilepsy</td>
</tr>
<tr>
<td colspan="1" rowspan="1">EEG</td>
<td colspan="1" rowspan="1">Irregular basal activity at 6–8 Hz, intermittent beta wave activity, focus in right hemispheric region centroparietal and frontotemporal, spike waves occipital left, focal morphology, without generalization</td>
<td colspan="1" rowspan="1">High-amplitude paroxysmal discharges at the vertex</td>
<td colspan="1" rowspan="1">NA</td>
<td colspan="1" rowspan="1">Sharp waves in frontotemporal regions</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Additional features/notes</td>
<td colspan="1" rowspan="1">NA</td>
<td colspan="1" rowspan="1">NA</td>
<td colspan="1" rowspan="1">CSF normal, tremor onset at 10 y, positional tremor and tremor of tongue, no intention tremor, progressive tremor, no pyramidal signs</td>
<td colspan="1" rowspan="1">NA</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tblfn1">
<p>Percentiles and standard deviations (SD) were calculated using <ext-link ext-link-type="uri" xlink:href="https://www.pedz.de">https://www.pedz.de</ext-link>. CPAP = continuous positive airway pressure; HC = head circumference; IPPV = intermittent positive pressure ventilation; IRDS = infant respiratory distress syndrome; MRS = magnetic resonance spectroscopy; NA = not available; NAA = N-acetyl aspartate; NICU = neonatal intensive care unit.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Variants Leu470Arg, Ser133Pro and Ser110Thr are located in the interface between the inhibitory switch domain and the catalytic domain (<xref ref-type="fig" rid="awz264-F1">Fig. 1</xref>). In each variant, the wild-type residue is replaced by a bulkier amino acid resulting in steric problems (‘clashes’) with adjacent amino acids, which destabilize the autoinhibitory domain and its interaction with the catalytic domain. Introducing arginine at p.Leu470, proline at p.Ser133, and threonine at p.Ser110 reduces binding by 1.76 kcal/mol, 1.26 kcal/mol, and 0.99 kcal/mol, respectively. The fourth variant, Pro121Ser, is located in the PAK1 dimer interface formed by the inhibitory switch domains of both subunits (<xref ref-type="fig" rid="awz264-F1">Fig. 1</xref> and <xref ref-type="supplementary-material" rid="sup1">Supplementary Fig. 1</xref>) and weakens binding by 2.30 kcal/mol. As a reference, an energy change of 1.36 kcal/mol corresponds to a reduction in binding affinity by one order of magnitude indicating that all three variants significantly destabilize the interaction between the inhibitory switch and the catalytic domain. In addition, the Pro121Ser variant is also expected to destabilize the autoinhibitory conformation of the switch domain itself: the rigid Pro121 with its cyclic sidechain is involved in the formation of a kink between two α-helices (<xref ref-type="fig" rid="awz264-F2">Fig. 2</xref>K), which is expected to become more flexible in the Ser121 variant. The inhibitory switch domain has been described as the core of the autoregulatory fragment, which appears to inhibit the kinase with one surface and anchor the dimer contact with another. Conformational changes in this highly conserved protein domain are likely to affect protein function. A loss of stability in the autoinhibitory domain, thereby reducing autoinhibition would be supportive of a gain-of-function mode of the observed genetic variants. A <italic>PAK1</italic> variant in the inhibitory switch domain, Leu107Phe, is already known to prevent the interaction between the N-terminal regulatory portion and catalytic domain, leading to kinase activation (<xref ref-type="bibr" rid="awz264-B3">Brown <italic>et al.</italic>, 1996</xref>).
</p>
<fig id="awz264-F2" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>
<bold>Brain MRI and facial features of individuals with heterozygous <italic>PAK1</italic> mutation.</bold> Brain MRIs of Proband 1 at age 2 years (<bold>A</bold>–<bold>D</bold>), Proband 2 at age 14 years (<bold>E</bold>–<bold>H</bold>), Proband 3 at age 12 years (<bold>I</bold>–<bold>L</bold>) and Proband 4 at age 8 years (<bold>M</bold>–<bold>P</bold>). Macrocephaly was caused by megalencephaly with or without accompanying ventriculomegaly. (<bold>A</bold>) T<sub>2</sub> mid-sagittal image showing a thin corpus callosum (arrow). (<bold>B</bold> and <bold>C</bold>) T<sub>2</sub> axial images showing ventriculomegaly (asterisks). (<bold>D</bold>) T<sub>1</sub> coronal image showing globular and mildly amorphous hippocampi bilaterally. (<bold>E</bold>) T<sub>1</sub> mid-sagittal image showing a thin corpus callosum and cerebellar atrophy with widening of the sulci (arrow). (<bold>F</bold> and <bold>G</bold>) T<sub>2</sub> axial images showing ventriculomegaly (asterisks). (<bold>H</bold>) T<sub>2</sub> coronal image showing mildly small and amorphous hippocampi bilaterally. (<bold>I</bold>) T<sub>1</sub> mid-sagittal image showing a thick corpus callosum (arrow). (<bold>J </bold>and <bold>K</bold>) T<sub>2</sub> axial images showing normal lateral ventricles. The white matter signal is slightly hyperintense in the posterior white matter, including the splenium (also present on FLAIR images, not shown). (<bold>L</bold>) T<sub>1</sub> coronal image showing normal volume and position of the hippocampi. At proton MR spectroscopy, <italic>N</italic>-acetyl aspartate was elevated (not shown). These findings were unchanged 9 months later. (<bold>M</bold>) T<sub>1</sub> mid-sagittal image showing macrocephaly and a thick corpus callosum (arrow). (<bold>N</bold>) T<sub>2</sub> axial image showing normal size of the lateral ventricles. (<bold>O</bold>) FLAIR axial image showing small foci of abnormal signal in frontal white matter may be related to old insult. (<bold>P</bold>) T<sub>1</sub> coronal image showing normal anatomy of the hippocampi. (<bold>Q</bold> and <bold>R</bold>) Photographs of Proband 3 at age 14 years with macrocephaly. (<bold>S</bold>) Photograph of Proband 4 at age 8 years with macrocephaly, facial muscular hypotonia and strabismus.</p>
</caption>
<graphic xlink:href="awz264f2"></graphic>
</fig>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>PAK1 is a family member of the serine/threonine p21-activating (PAK) kinases composed of six known members in humans, PAK1–6. These proteins are critical effectors that link RhoGTPases to cytoskeleton reorganization and nuclear signalling and other intracellular processes (<xref ref-type="bibr" rid="awz264-B17">Manser <italic>et al.</italic>, 1998</xref>; <xref ref-type="bibr" rid="awz264-B32">Zhao and Manser, 2012</xref>; <xref ref-type="bibr" rid="awz264-B25">Rane and Minden, 2014</xref>). Both PAK1 and PAK3 have been reported to control brain size through coordinating neuronal complexity and synaptic properties (<xref ref-type="bibr" rid="awz264-B11">Huang <italic>et al.</italic>, 2011</xref>). Nonsense and missense variants that are thought to decrease autophosphorylation and activation of PAK3 have been described in males with X-linked recessive developmental delay (MIM: 300558). Recently, two probands with a neurodevelopmental disorder and <italic>de novo</italic> missense variants in <italic>PAK1</italic> have been described. Their phenotype is similar to the phenotype presented by our probands with developmental delay, macrocephaly, seizures, and ataxic gait (<xref ref-type="bibr" rid="awz264-B8">Harms <italic>et al.</italic>, 2018</xref>). The described variants p.(Tyr131Cys) and p.(Tyr429Cys) are located in the autoinhibitory and kinase domains of PAK1 similarly to the <italic>de novo</italic> variants presented in our study. <xref ref-type="bibr" rid="awz264-B8">Harms <italic>et al.</italic> (2018)</xref> furthermore showed that both variants lead to significantly reduced dimerization, providing evidence for a gain-of-function pathomechanism. Our results on the location of variants and the predicted effects on the protein provide additional evidence for this pathomechanism.</p>
<p>
<italic>PAK1</italic> is central to a well-described signalling pathway and an involvement in neurodevelopmental disorders was also described for other members of the pathway. Interacting partners of PAK1, especially the PAK1 activators RAC1 and CDC42, have been associated with developmental syndromes (<xref ref-type="fig" rid="awz264-F3">Fig. 3</xref> and <xref ref-type="supplementary-material" rid="sup1">Supplementary Table 2</xref>). <italic>De novo </italic>pathogenic missense <italic>RAC1</italic> variants are associated with varying degrees of developmental delay, brain malformations, and additional phenotypes in autosomal dominant mental retardation 48 (MIM: 617751). Notably, of the seven reported affected individuals, two were macrocephalic; however, without a clear effect of protein activation. Pathogenic, heterozygous <italic>de novo</italic> or familial variants in <italic>CDC42</italic> cause a highly heterogeneous developmental disorder (MIM: 616737). Some individuals with <italic>CDC42</italic> variants showed a broad forehead; however again, carrying both activating and deactivating variants.
</p>
<fig id="awz264-F3" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>
<bold>Involvement of the PAK1 pathway in developmental phenotypes.</bold> RAC1 and CDC42 are direct activators, TRIO and HACE1 are indirect (via RAC1) regulators of PAK1. ARHGEF6 binds PAK1 for regulation of neurite outgrowth. PAK1 activates LIMK1, the regulator of PAK1 downstream effectors cofilin (CFL2) and tubulin cofactor B. Disorders associated with deactivating and/or activating variants for each gene are indicated in grey with the respective mode of inheritance given (see <xref ref-type="supplementary-material" rid="sup1">Supplementary Table 2</xref> for details and phenotypic overlap). Green shaded box indicates activation of RAC1-PAK1-LIMK1 pathway in FXS, where macrocephaly also occurs. Currently available inhibitors of PAK1 are indicated.</p>
</caption>
<graphic xlink:href="awz264f3"></graphic>
</fig>
<p>Variants in <italic>TRIO</italic> and <italic>HACE1</italic>, known interactors of RAC1, are mainly reported as loss-of-function variants (MIM: 617061 and MIM: 616756). Notably, the PAK1-pathway is presumably activated in <italic>HACE1</italic> deficiency neurodevelopmental syndrome (<xref ref-type="bibr" rid="awz264-B10">Hollstein <italic>et al.</italic>, 2015</xref>) and the disorder resembles many of the symptoms described in this study, excluding macrocephaly, though one <italic>HACE1</italic> patient had a large head circumference at birth (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table 2</xref>). To determine other interactors of PAK1 we identified genes that show an expression associated with that of <italic>PAK1</italic> and that code for proteins that physically interact with PAK1 (<xref ref-type="supplementary-material" rid="sup1">Supplementary Fig. 2</xref>). Additionally <italic>ARHGEF6</italic> has been associated with a neurodevelopmental disorder (MIM: 300436). <italic>ARHGEF6</italic> encodes the Rac/Cdc42 guanine nucleotide exchange factor 6 (PIX) (<xref ref-type="bibr" rid="awz264-B17">Manser <italic>et al.</italic>, 1998</xref>), which can bind to PAK1 for the mediation of neurite outgrowth (<xref ref-type="bibr" rid="awz264-B25">Rane and Minden, 2014</xref>). A role of PAK1 in neuronal growth is also supported by MRI data of our probands. <italic>N</italic>-acetyl aspartate (NAA) is a key metabolite and marker of intact neurons. Increased total levels of NAA were detected in the MRI of Proband 3 and could possibly be related to the increased growth of neurons as a cause of megalencephaly in <italic>PAK1</italic>-related disorders. Amorphous hippocampi were present in two of four probands (Probands 1 and 2). It has been shown previously that PAK1 is critical in hippocampal synaptic plasticity by the regulation of cofilin activity and the actin cytoskeleton (<xref ref-type="bibr" rid="awz264-B1">Asrar <italic>et al.</italic>, 2009</xref>). Hence, altered PAK1 activity may result in morphological changes of hippocampi, a feature that could be tested in future patients.</p>
<p>
<italic>PAK1</italic> is highly expressed in the human cerebellum and cortex and studies have described its role in neuronal migration by activating its downstream targets: LIMK1, cofilins and tubulin cofactor B (<xref ref-type="bibr" rid="awz264-B27">Sells <italic>et al.</italic>, 1997</xref>; <xref ref-type="bibr" rid="awz264-B6">Delorme <italic>et al.</italic>, 2007</xref>; <xref ref-type="bibr" rid="awz264-B18">Martinelli <italic>et al.</italic>, 2018</xref>). PAK1 phosphorylation of tubulin cofactor B is essential for the polymerization of new microtubules, which is important for building and re-building neuronal structures (<xref ref-type="bibr" rid="awz264-B7">Edwards <italic>et al.</italic>, 1999</xref>; <xref ref-type="bibr" rid="awz264-B29">Vadlamudi <italic>et al.</italic>, 2005</xref>). PAK1 activates LIMK1 that plays a critical role in dendritic spine morphogenesis and brain function by phosphorylation and deactivation of cofilin (<xref ref-type="bibr" rid="awz264-B20">Meng <italic>et al.</italic>, 2002</xref>). Cofilin can directly bind to actin filaments and promote their disassembly, needed for the reorganization of actin networks during neuronal growth (<xref ref-type="bibr" rid="awz264-B4">Chen <italic>et al.</italic>, 2011</xref>). Consequently, increased activity of PAK1 in our probands would lead to increased activity of LIMK and thereby reduced actin dynamics via cofilin.</p>
<p>Recently, it was shown that the inherited intellectual disability and autism-associated FXS (MIM: 300624) is characterized by activated PAK1 (<xref ref-type="bibr" rid="awz264-B24">Pyronneau <italic>et al.</italic>, 2017</xref>). Intriguingly, the characteristic loss of the mRNA-binding protein FMR1 increased the abundance and activity of Rac1 in mice. Rac1 activated the kinases Pak1 and Limk1, which inactivated cofilin, thus preventing actin depolymerization dynamics (<xref ref-type="bibr" rid="awz264-B9">Hayashi <italic>et al.</italic>, 2007</xref>; <xref ref-type="bibr" rid="awz264-B24">Pyronneau <italic>et al.</italic>, 2017</xref>). Both macrocephaly and seizures are also typically present in FXS, underscoring a similarity of phenotypes in patients with mutations in <italic>PAK1</italic> and FXS.</p>
<p>Another piece of evidence supporting a gain-of-function mechanism for the identified variants in our patients is that <italic>PAK1</italic> homozygous knockout (<italic>Pak1</italic><sup>−/−</sup>) mice appear to be viable with no gross abnormalities. Human and mouse <italic>PAK1</italic> genes are extremely well conserved, being 98% identical. <italic>Pak1</italic><sup>−/−</sup> mice have some metabolic abnormal phenotypes, mainly increased blood urea levels, increased triglycerides, decreased lean body mass and decreased bone mineral content, and decreased neutrophils; however, no neurodevelopmental abnormalities or abnormal head size were reported (<ext-link ext-link-type="uri" xlink:href="http://www.mousephenotype.org/data/genes/MGI:1339975">http://www.mousephenotype.org/data/genes/MGI:1339975</ext-link>). The fact that loss-of-function variants of <italic>PAK1</italic> are tolerated in human populations (pLI = 0.67) (<xref ref-type="bibr" rid="awz264-B12">Karczewski <italic>et al.</italic>, 2016</xref>) also indicates that this may not represent a prevailing pathomechanism of PAK1-associated disease.</p>
<p>Several inhibitors of PAK1 are currently under development and comprise ATP-competitive inhibitors, such as FRAX597 and FRAX486, which block ATP binding at the catalytic domain of PAK1 (<xref ref-type="bibr" rid="awz264-B26">Sampat and Minden, 2018</xref>). Dibenzodiazepines inhibit PAK1 by preventing its autophosphorylation (<xref ref-type="bibr" rid="awz264-B13">Karpov <italic>et al.</italic>, 2015</xref>). If <italic>PAK1</italic>-associated disease proves to exhibit a gain-of-function mechanism, novel options for the treatment of affected patients could arise.</p>
<p>The importance of <italic>PAK1</italic> in neuronal growth and structure, the positions and amino acids affected by the four identified genetic variants and their predicted effects on the protein, the strongly overlapping phenotypes of the affected individuals, as well as previously published data on other members of the <italic>PAK1</italic>-associated pathway allow us to consider that the <italic>de novo</italic> variants in <italic>PAK1</italic> discovered in this study are the cause of a neurodevelopmental disorder characterized by intellectual disability with macrocephaly and seizures.</p>
</sec>
<sec>
<title>Web resources</title>
<p>Genematcher, <ext-link ext-link-type="uri" xlink:href="https://genematcher.org/">https://genematcher.org/</ext-link></p>
<p>GnomAD, <ext-link ext-link-type="uri" xlink:href="http://gnomad.broadinstitute.org/">http://gnomad.broadinstitute.org/</ext-link></p>
<p>VARVIS, <ext-link ext-link-type="uri" xlink:href="https://www.limbus-medtec.com/">https://www.limbus-medtec.com/</ext-link></p>
<p>UCSC Genome Browser, <ext-link ext-link-type="uri" xlink:href="https://genome.ucsc.edu/">https://genome.ucsc.edu/</ext-link></p>
<p>HGMD, <ext-link ext-link-type="uri" xlink:href="https://portal.biobase-international.com/cgi-bin/portal/login.cgi?redirect_url=/hgmd/pro/start.php?">https://portal.biobase-international.com/cgi-bin/portal/login.cgi?redirect_url=/hgmd/pro/start.php?</ext-link></p>
<p>PolyPhen-2, <ext-link ext-link-type="uri" xlink:href="http://genetics.bwh.harvard.edu/pph2/">http://genetics.bwh.harvard.edu/pph2/</ext-link></p>
<p>MutationTaster, <ext-link ext-link-type="uri" xlink:href="http://www.mutationtaster.org/">http://www.mutationtaster.org/</ext-link></p>
<p>CADD, <ext-link ext-link-type="uri" xlink:href="http://cadd.gs.washington.edu/score">http://cadd.gs.washington.edu/score</ext-link></p>
<p>R2, <ext-link ext-link-type="uri" xlink:href="https://hgserver1.amc.nl/cgi-bin/r2/main.cgi">https://hgserver1.amc.nl/cgi-bin/r2/main.cgi</ext-link></p>
<p>NCBI Pubmed, <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/">https://www.ncbi.nlm.nih.gov/pubmed/</ext-link></p>
<p>Pedz, <ext-link ext-link-type="uri" xlink:href="https://www.pedz.de">https://www.pedz.de</ext-link></p>
<p>Online Mendelian Inheritance in Man, <ext-link ext-link-type="uri" xlink:href="http://www.omim.org/">http://www.omim.org/</ext-link></p>
<p>Genemania, <ext-link ext-link-type="uri" xlink:href="https://genemania.org">https://genemania.org</ext-link></p>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="sup1">
<label>awz264_Supplementary_Data</label>
<media xlink:href="awz264_supplementary_data.pdf">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</body>
<back>
<ack id="ack1">
<title>Acknowledgements</title>
<p>We thank the families and referring physicians for their participation in this study. We thank Julia Hentschel for technical assistance.</p>
</ack>
<glossary>
<def-list>
<title>Abbreviation</title>
<def-item>
<term id="G1">FXS</term>
<def>
<p>fragile X syndrome</p>
</def>
</def-item>
</def-list>
</glossary>
<sec>
<title>Funding</title>
<p>Research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke (NINDS) under award number K08NS092898 and Jordan’s Guardian Angels (to G.M.). The content is solely the responsibility of the authors, and does not necessarily represent the official views of the National Institutes of Health. The funding sources had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, preparation, review or approval of the manuscript, or decision to submit the manuscript for publication.</p>
</sec>
<sec>
<title>Competing interests</title>
<p>C.G-J. is a full-time employee of the Regeneron Genetics Center from Regeneron Pharmaceuticals Inc. and receives stock options as part of compensation. A.C. and C.M. are employed by and receive a salary from ARUP Laboratories. P.B-T. is a consultant to ARUP Laboratories. The other authors declare no conflict of interest.</p>
</sec>
<ref-list id="ref1">
<title>References</title>
<ref id="awz264-B1">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Asrar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Meng</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Todorovski</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>WW</given-names></name>, <name name-style="western"><surname>Jia</surname><given-names>Z</given-names></name></person-group>
<article-title>Regulation of hippocampal long-term potentiation by p21-activated protein kinase 1 (PAK1)</article-title>. <source/>Neuropharmacology<year>2009</year>; <volume>56</volume>: <fpage>73</fpage>–<lpage>80</lpage>.</mixed-citation>
</ref>
<ref id="awz264-B2">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Boycott</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Rath</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chong</surname><given-names>JX</given-names></name>, <name name-style="western"><surname>Hartley</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Alkuraya</surname><given-names>FS</given-names></name>, <name name-style="western"><surname>Baynam</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal><article-title>International cooperation to enable the diagnosis of all rare genetic diseases</article-title>. <source/>Am J Hum Genet<year>2017</year>; <volume>100</volume>: <fpage>695</fpage>–<lpage>705</lpage>.<pub-id pub-id-type="pmid">28475856</pub-id></mixed-citation>
</ref>
<ref id="awz264-B3">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Stowers</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Baer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Trejo</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Coughlin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chant</surname><given-names>J</given-names></name></person-group>
<article-title>Human Ste20 homologue hPAK1 links GTPases to the JNK MAP kinase pathway</article-title>. <source/>Curr Biol<year>1996</year>; <volume>6</volume>: <fpage>598</fpage>–<lpage>605</lpage>.<pub-id pub-id-type="pmid">8805275</pub-id></mixed-citation>
</ref>
<ref id="awz264-B4">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S-Y</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>P-H</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>H-J</given-names></name></person-group>
<article-title>Disrupted-in-schizophrenia 1–mediated axon guidance involves TRIO-RAC-PAK small GTPase pathway signaling</article-title>. <source/>Proc Natl Acad Sci<year>2011</year>; <volume>108</volume>: <fpage>5861</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">21422296</pub-id></mixed-citation>
</ref>
<ref id="awz264-B5">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>De Ligt</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Willemsen</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>van Bon</surname><given-names>BWM</given-names></name>, <name name-style="western"><surname>Kleefstra</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Yntema</surname><given-names>HG</given-names></name>, <name name-style="western"><surname>Kroes</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal><article-title>Diagnostic exome sequencing in persons with severe intellectual disability</article-title>. <source/>N Engl J Med<year>2012</year>; <volume>367</volume>: <fpage>1921</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">23033978</pub-id></mixed-citation>
</ref>
<ref id="awz264-B6">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Delorme</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Machacek</surname><given-names>M</given-names></name>, <name name-style="western"><surname>DerMardirossian</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Wittmann</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hanein</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal><article-title>Cofilin activity downstream of Pak1 regulates cell protrusion efficiency by organizing lamellipodium and lamella actin networks</article-title>. <source/>Dev Cell<year>2007</year>; <volume>13</volume>: <fpage>646</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">17981134</pub-id></mixed-citation>
</ref>
<ref id="awz264-B7">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Sanders</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Bokoch</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Gill</surname><given-names>GN</given-names></name></person-group>
<article-title>Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics</article-title>. <source/>Nat Cell Biol<year>1999</year>; <volume>1</volume>: <fpage>253</fpage>.<pub-id pub-id-type="pmid">10559936</pub-id></mixed-citation>
</ref>
<ref id="awz264-B8">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Harms</surname><given-names>FL</given-names></name>, <name name-style="western"><surname>Kloth</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Bley</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Denecke</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Santer</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lessel</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal><article-title>Activating mutations in PAK1, encoding p21-activated kinase 1, cause a neurodevelopmental disorder</article-title>. <source/>Am J Hum Genet<year>2018</year>; <volume>103</volume>: <fpage>579</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">30290153</pub-id></mixed-citation>
</ref>
<ref id="awz264-B9">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hayashi</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Rao</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Seo</surname><given-names>J-S</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>H-S</given-names></name>, <name name-style="western"><surname>Dolan</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>S-Y</given-names></name></person-group>, <etal>et al</etal><article-title>Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice</article-title>. <source/>Proc Natl Acad Sci<year>2007</year>; <volume>104</volume>: <fpage>11489</fpage>–<lpage>94</lpage>.<pub-id pub-id-type="pmid">17592139</pub-id></mixed-citation>
</ref>
<ref id="awz264-B10">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hollstein</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Parry</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Nalbach</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Logan</surname><given-names>CV</given-names></name>, <name name-style="western"><surname>Strom</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Hartill</surname><given-names>VL</given-names></name></person-group>, <etal>et al</etal><article-title>HACE1 deficiency causes an autosomal recessive neurodevelopmental syndrome</article-title>. <source/>J Med Genet<year>2015</year>; <volume>52</volume>: <fpage>797</fpage>–<lpage>803</lpage>.<pub-id pub-id-type="pmid">26424145</pub-id></mixed-citation>
</ref>
<ref id="awz264-B11">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Asrar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Henkelman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Jia</surname><given-names>Z</given-names></name></person-group>
<article-title>p21-Activated kinases 1 and 3 control brain size through coordinating neuronal complexity and synaptic properties</article-title>. <source/>Mol Cell Biol<year>2011</year>; <volume>31</volume>: <fpage>388</fpage>–<lpage>403</lpage>.<pub-id pub-id-type="pmid">21115725</pub-id></mixed-citation>
</ref>
<ref id="awz264-B12">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Karczewski</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Weisburd</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Solomonson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ruderfer</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Kavanagh</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal><article-title>The ExAC browser. Displaying reference data information from over 60 000 exomes</article-title>. <source/>Nucl Acids Res<year>2016</year>; <volume>45</volume>: <fpage>D840</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">27899611</pub-id></mixed-citation>
</ref>
<ref id="awz264-B13">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Karpov</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Amiri</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bellamacina</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Bellance</surname><given-names>M-H</given-names></name>, <name name-style="western"><surname>Breitenstein</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Daniel</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal><article-title>Optimization of a dibenzodiazepine hit to a potent and selective allosteric PAK1 inhibitor</article-title>. <source/>ACS Med Chem Lett<year>2015</year>; <volume>6</volume>: <fpage>776</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="pmid">26191365</pub-id></mixed-citation>
</ref>
<ref id="awz264-B14">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kircher</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Witten</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Jain</surname><given-names>P</given-names></name>, <name name-style="western"><surname>O’roak</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Cooper</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Shendure</surname><given-names>J</given-names></name></person-group>
<article-title>A general framework for estimating the relative pathogenicity of human genetic variants</article-title>. <source/>Nat Genet<year>2014</year>; <volume>46</volume>: <fpage>310</fpage>.<pub-id pub-id-type="pmid">24487276</pub-id></mixed-citation>
</ref>
<ref id="awz264-B15">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Meng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Parrini</surname><given-names>M-C</given-names></name>, <name name-style="western"><surname>Eck</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Mayer</surname><given-names>BJ</given-names></name></person-group>, <etal>et al</etal><article-title>Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch</article-title>. <source/>Cell<year>2000</year>; <volume>102</volume>: <fpage>387</fpage>–<lpage>97</lpage>.<pub-id pub-id-type="pmid">10975528</pub-id></mixed-citation>
</ref>
<ref id="awz264-B16">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lek</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Karczewski</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Minikel</surname><given-names>EV</given-names></name>, <name name-style="western"><surname>Samocha</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Banks</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Fennell</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal><article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title>. <source/>Nature<year>2016</year>; <volume>536</volume>: <fpage>285</fpage>.<pub-id pub-id-type="pmid">27535533</pub-id></mixed-citation>
</ref>
<ref id="awz264-B17">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Manser</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Loo</surname><given-names>T-H</given-names></name>, <name name-style="western"><surname>Koh</surname><given-names>C-G</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Z-S</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>X-Q</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal><article-title>PAK kinases are directly coupled to the PIX family of nucleotide exchange factors</article-title>. <source/>Mol Cell<year>1998</year>; <volume>1</volume>: <fpage>183</fpage>–<lpage>92</lpage>.<pub-id pub-id-type="pmid">9659915</pub-id></mixed-citation>
</ref>
<ref id="awz264-B18">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Martinelli</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Krumbach</surname><given-names>OHF</given-names></name>, <name name-style="western"><surname>Pantaleoni</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Coppola</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Amin</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Pannone</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal><article-title>Functional dysregulation of CDC42 causes diverse developmental phenotypes</article-title>. <source/>Am J Hum Genet<year>2018</year>; <volume>102</volume>: <fpage>309</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">29394990</pub-id></mixed-citation>
</ref>
<ref id="awz264-B19">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Maulik</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Mascarenhas</surname><given-names>MN</given-names></name>, <name name-style="western"><surname>Mathers</surname><given-names>CD</given-names></name>, <name name-style="western"><surname>Dua</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Saxena</surname><given-names>S</given-names></name></person-group>
<article-title>Prevalence of intellectual disability. A meta-analysis of population-based studies</article-title>. <source/>Res Dev Disabil<year>2011</year>; <volume>32</volume>: <fpage>419</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">21236634</pub-id></mixed-citation>
</ref>
<ref id="awz264-B20">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Tregoubov</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Janus</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cruz</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Jackson</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal><article-title>Abnormal spine morphology and enhanced LTP in LIMK-1 knockout mice</article-title>. <source/>Neuron<year>2002</year>; <volume>35</volume>: <fpage>121</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">12123613</pub-id></mixed-citation>
</ref>
<ref id="awz264-B21">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Parrini</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Lei</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Harrison</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Mayer</surname><given-names>BJ</given-names></name></person-group>
<article-title>Pak1 kinase homodimers are autoinhibited in trans and dissociated upon activation by Cdc42 and Rac1</article-title>. <source/>Mol Cell<year>2002</year>; <volume>9</volume>: <fpage>73</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="pmid">11804587</pub-id></mixed-citation>
</ref>
<ref id="awz264-B22">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pettersen</surname><given-names>EF</given-names></name>, <name name-style="western"><surname>Goddard</surname><given-names>TD</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Couch</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Greenblatt</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Meng</surname><given-names>EC</given-names></name></person-group>, <etal>et al</etal><article-title>UCSF Chimera—a visualization system for exploratory research and analysis</article-title>. <source/>J Comput Chem<year>2004</year>; <volume>25</volume>: <fpage>1605</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">15264254</pub-id></mixed-citation>
</ref>
<ref id="awz264-B23">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pirruccello</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sondermann</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Pelton</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Pellicena</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Hoelz</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chernoff</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal><article-title>A dimeric kinase assembly underlying autophosphorylation in the p21 activated kinases</article-title>. <source/>J Mol Biol<year>2006</year>; <volume>361</volume>: <fpage>312</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">16837009</pub-id></mixed-citation>
</ref>
<ref id="awz264-B24">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pyronneau</surname><given-names>A</given-names></name>, <name name-style="western"><surname>He</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Hwang</surname><given-names>J-Y</given-names></name>, <name name-style="western"><surname>Porch</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Contractor</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Zukin</surname><given-names>RS</given-names></name></person-group>
<article-title>Aberrant Rac1-cofilin signaling mediates defects in dendritic spines, synaptic function, and sensory perception in fragile X syndrome</article-title>. <source/>Sci Signal<year>2017</year>; <volume>10</volume>: <fpage>eaan0852</fpage>.<pub-id pub-id-type="pmid">29114038</pub-id></mixed-citation>
</ref>
<ref id="awz264-B25">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rane</surname><given-names>CK</given-names></name>, <name name-style="western"><surname>Minden</surname><given-names>A</given-names></name></person-group>
<article-title>P21 activated kinases. Structure, regulation, and functions</article-title>. <source/>Small GTPases<year>2014</year>; <volume>5</volume>: <fpage>e28003</fpage>.<pub-id pub-id-type="pmid">24658305</pub-id></mixed-citation>
</ref>
<ref id="awz264-B26">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sampat</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Minden</surname><given-names>A</given-names></name></person-group>
<article-title>Inhibitors of the p21 activated kinases</article-title>. <source/>Curr Pharmacol Rep<year>2018</year>; <volume>4</volume>: <fpage>238</fpage>–<lpage>49</lpage>.</mixed-citation>
</ref>
<ref id="awz264-B27">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sells</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Knaus</surname><given-names>UG</given-names></name>, <name name-style="western"><surname>Bagrodia</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ambrose</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Bokoch</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Chernoff</surname><given-names>J</given-names></name></person-group>
<article-title>Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells</article-title>. <source/>Curr Biol<year>1997</year>; <volume>7</volume>: <fpage>202</fpage>–<lpage>10</lpage>.</mixed-citation>
</ref>
<ref id="awz264-B28">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Trujillano</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bertoli-Avella</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Kandaswamy</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Weiss</surname><given-names>MER</given-names></name>, <name name-style="western"><surname>Köster</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Marais</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal><article-title>Clinical exome sequencing. Results from 2819 samples reflecting 1000 families</article-title>. <source/>Eur J Hum Genet<year>2017</year>; <volume>25</volume>: <fpage>176</fpage>.<pub-id pub-id-type="pmid">27848944</pub-id></mixed-citation>
</ref>
<ref id="awz264-B29">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Vadlamudi</surname><given-names>RK</given-names></name>, <name name-style="western"><surname>Barnes</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Rayala</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Balasenthil</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Marcus</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal><article-title>p21-activated kinase 1 regulates microtubule dynamics by phosphorylating tubulin cofactor B</article-title>. <source/>Mol Cell Biol<year>2005</year>; <volume>25</volume>: <fpage>3726</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">15831477</pub-id></mixed-citation>
</ref>
<ref id="awz264-B30">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Vissers</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>Gilissen</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Veltman</surname><given-names>JA</given-names></name></person-group>
<article-title>Genetic studies in intellectual disability and related disorders</article-title>. <source/>Nature Rev Genet<year>2016</year>; <volume>17</volume>: <fpage>9</fpage>.<pub-id pub-id-type="pmid">26503795</pub-id></mixed-citation>
</ref>
<ref id="awz264-B31">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name></person-group>
<article-title>BindProfX. Assessing mutation-induced binding affinity change by protein interface profiles with pseudo-counts</article-title>. <source/>J Mol Biol<year>2017</year>; <volume>429</volume>: <fpage>426</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">27899282</pub-id></mixed-citation>
</ref>
<ref id="awz264-B32">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Z-S</given-names></name>, <name name-style="western"><surname>Manser</surname><given-names>E</given-names></name></person-group>
<article-title>PAK family kinases. Physiological roles and regulation</article-title>. <source/>Cell Logist<year>2012</year>; <volume>2</volume>: <fpage>59</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="pmid">23162738</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>